Mumbai-based BDR Pharmaceuticals International has announced the launch of Dalbonova Injection. A revolutionary medication for the treatment of acute bacterial skin and skin structure infections caused by designated susceptible strains of Gram-positive microorganisms.

This ground breaking drug will be available as a 500 mg injection and marks an important milestone in the field of anti-infective medicines in India.

According to the latest data from the World Health Organisation (WHO), in 2023 there were an estimated 11.5 million cases of acute bacterial skin and skin structure infections (ABSSSI) in India. This represents a 15% increase in the number of cases from 2022. The male-to-female ratio for ABSSSI in India is 1.2:1. This means that men are about 20% more likely to develop ABSSSI than women. Children under the age of five and people over the age of 65 throughout India have the highest incidence of ABSSSI. 

Dalbonova revolutionises medical treatment with its single-dose therapy for ABSSSI in patients of all ages, including newborns. Unlike traditional methods involving multiple infusions over days, Dalbonova's dosing regimen offers remarkable convenience and effectiveness. Patients can opt for a potent single-dose of 1500 mg or a comprehensive two-dose regimen of 1000 mg followed by 500 mg after one week, catering to individual needs.